A sustainable biotechnology platform using insect larvae to biodegrade natural and synthetic polymer films while generating high-value end products including proteins, oils, chitin, and chitosan. The approach leverages insect gut microbiota consortia for efficient polymer decomposition with applications in packaging, cosmetics, pharmaceuticals, and wood products.
This research proposes an innovative biotechnology platform that uses insect larvae to biodegrade biodegradable films while producing high-value molecules suitable for multiple industries. The approach exploits the natural digestive capabilities of insects, whose gut microbiota—including bacteria, fungi, archaea, and protists—work together with endogenous enzymes to break down complex polymers.
The solution addresses two challenges simultaneously: sustainable management of biodegradable polymer waste and production of valuable biomolecules. End products include proteins, lipids, chitin, and chitosan with applications in packaging, cosmetics, and pharmaceuticals. Insect proteins may also serve as sustainable alternatives to phenol in plywood manufacturing.
Core approach:
High-value end products:
Research capabilities:
The research is at an early-to-mid development stage. The team has established expertise in insect breeding, physiology, and symbiont interactions, building on published evidence that larvae of Lepidoptera, Coleoptera, and Diptera can biodegrade various polymers. Future validation will involve setting up insect rearings on different biodegradable films, assessing larval growth performance and substrate mass reduction, analyzing microbiota adaptation, and characterizing the protein, lipid, and bioactive composition of mature larvae. The research team is actively seeking partners for chemical analyses and conversion/reuse of high-value final products.
The University of Turin is a comprehensive public research university with a broad disciplinary footprint and strong regional engagement. Industry connects through a dedicated knowledge‑transfer function and 2i3T, the university’s business incubator and technology‑transfer company, which supports IP protection, licensing and spin‑out creation. Clinical translation is enabled by integration with the Città della Salute e della Scienza di Torino, a large university hospital system. Situated in a metropolitan area anchored by leading automotive and aerospace players, the university collaborates within a mature industrial ecosystem. Research is supported by competitive European and national funding, including Horizon Europe and Italian ministerial programs.